# US 2025/0163369 A1 · Differentiation induction control agent and differentiation induction stabilizing agent for pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0163369 A1
- Document ID: US20250163369A1
- Status: Published application
- Kind: A1
- Application number: 18/836,633
- Filed: 2023-02-06
- Published: 2025-05-22
- Earliest claimed: 2022-02-07
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Masahiro KINOOKA; Meehae KIM; Yukako FUJINAGA
- Web page: https://patentgrep.com/patent/US20250163369A1

## CPC

- C12N 5/0608: {Germ cells (production of embryos, nuclear transfer A01K67/027)}
- C12N 5/067: {Hepatocytes}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0621: {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/237: Oncostatin M [OSM]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/58: Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
- C12N 2501/585: Integrins
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An agent for directional control of differentiation induction of a pluripotent stem cell, which contains an E-cadherin inhibitor, and its uses are disclosed. A method for controlling the directionality of differentiation induction of a pluripotent stem cell is also disclosed. The method includes a step of culturing a pluripotent stem cell in a medium comprising an E-cadherin inhibitor.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A method for controlling the directionality of differentiation induction of a pluripotent stem cell, comprising a step of culturing a pluripotent stem cell in a medium comprising an E-cadherin inhibitor.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the culture is performed in the presence of a differentiation inducer.

### Claim 8 (depends on 6)

The method according to claim 6, wherein, in the step of culturing a pluripotent stem cell in a medium comprising an E-cadherin inhibitor, a concentration of the inhibitor is adjusted.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the directional control of differentiation induction of pluripotent stem cell is a change in the differentiation efficiency of pluripotent stem cell into any of the three germ lineages.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the E-cadherin inhibitor is hemagglutinin.

### Claim at position 7

11-14. (canceled)

### Claim 15

A method for producing a desired differentiated cell from a pluripotent stem cell, comprising the following steps:
(1) a step of forming an aggregate of pluripotent stem cells, and
(2) a step of culturing the aggregates obtained in step (1) in a medium comprising an E-cadherin inhibitor, thereby to stabilize the differentiation induction into the desired differentiated cell.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the culture is performed in the presence of a differentiation inducer.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the pluripotent stem cell is an ES cell or an iPS cell.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the E-cadherin inhibitor is hemagglutinin.
